Loading...

Paul M Beringer, PharmD

TitleDepartment Chair of The Department of Clinical Pharmacy
InstitutionUniversity of Southern California
DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
AddressPSC B15
Health Sciences Campus
Los Angeles CA 90089-9121
Phone+1 323 442 1402
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Beringer’s research focus is on cystic fibrosis, a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Dr. Beringer’s group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.

    Ongoing research projects include: the study of the mechanistic basis of the enhanced renal clearance of antibiotics in CF; the use of novel clinical measures of glomerular filtration to improve drug dosing; and impact of pancreatic insufficiency on oral bioavailability of antibiotics.

    Biography: Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).

    Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Park AYJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer P. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2018 Jun 18. PMID: 29914949.
      View in: PubMed
    2. Jayne JG, Bensman TJ, Schaal JB, Park AYJ, Kimura E, Tran D, Selsted ME, Beringer P. Rhesus ?-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol. 2018 Mar; 58(3):310-319. PMID: 28954201.
      View in: PubMed
    3. Schaal JB, Tran DQ, Subramanian A, Patel R, Laragione T, Roberts KD, Trinh K, Tongaonkar P, Tran PA, Minond D, Fields GB, Beringer P, Ouellette AJ, Gulko PS, Selsted ME. Suppression and resolution of autoimmune arthritis by rhesus ?-defensin-1, an immunomodulatory macrocyclic peptide. PLoS One. 2017; 12(11):e0187868. PMID: 29145473.
      View in: PubMed
    4. Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer P. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2017 Oct; 61(10). PMID: 28784670.
      View in: PubMed
    5. Bensman TJ, Jayne JG, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, Beringer P. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother. 2017 08; 61(8). PMID: 28559270.
      View in: PubMed
    6. Beringer P, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. Rhesus ?-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2016 Jan; 71(1):181-8. PMID: 26433781; PMCID: PMC5007590 [Available on 01/01/17].
    7. Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer P, Neamati N. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. J Chem Inf Model. 2015 Aug 24; 55(8):1720-38. PMID: 26153616.
      View in: PubMed
    8. Ha H, Bensman T, Ho H, Beringer P, Neamati N. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol. 2014 Mar; 171(6):1551-65. PMID: 24354854; PMCID: PMC3954492.
    9. Bensman TJ, Nguyen AN, Rao AP, Beringer P. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther. 2012 Oct; 25(5):377-82. PMID: 22771903.
      View in: PubMed
    10. Acute care clinical pharmacy practice: unit- versus service-based models. Pharmacotherapy. 2012 Feb; 32(2):e35-44. PMID: 22392430.
      View in: PubMed
    11. Beringer P, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan; 56(1):70-4. PMID: 22024822; PMCID: PMC3256044.
    12. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 Jul; 55(7):3278-83. PMID: 21576448; PMCID: PMC3122454.
    13. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011 Feb; 37(2):95-101. PMID: 21130609.
      View in: PubMed
    14. Beringer P, Owens H, Nguyen A, Mordwinkin N, Louie S, Mak M, Sattler F. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy. 2010 Oct; 30(10):1004-10. PMID: 20874037.
      View in: PubMed
    15. Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R. Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy. 2009 Feb; 29(2):236-44. PMID: 19170592.
      View in: PubMed
    16. Beringer P, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Jan; 8(1):19-25. PMID: 18799365.
      View in: PubMed
    17. Beringer P, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul; 28(7):883-94. PMID: 18576903.
      View in: PubMed
    18. Liu S, Beringer P, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol. 2008 Aug; 48(8):957-65. PMID: 18511651.
      View in: PubMed
    19. Han EE, Beringer P, Falck P, Louie S, Rao P, Shapiro B, Gill M. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Antimicrob Chemother. 2006 May; 57(5):1017-9. PMID: 16533828.
      View in: PubMed
    20. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005 Dec; 49(12):5013-7. PMID: 16304166; PMCID: PMC1315964.
    21. Wong-Beringer A, Lambros MP, Beringer P, Johnson DL. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest. 2005 Nov; 128(5):3711-6. PMID: 16304338.
      View in: PubMed
    22. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005 Sep; 49(9):3676-81. PMID: 16127039; PMCID: PMC1195442.
    23. Beringer P, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother. 2005 Jun; 39(6):1097-108. PMID: 15886292.
      View in: PubMed
    24. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. PMID: 15809878.
      View in: PubMed
    25. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar; 11(3):244-52. PMID: 15001403.
      View in: PubMed
    26. Han EE, Beringer P, Louie SG, Gill MA, Shapiro BJ. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin Pharmacokinet. 2004; 43(3):145-56. PMID: 14871154.
      View in: PubMed
    27. Sprauten PF, Beringer P, Louie SG, Synold TW, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother. 2003 Jun; 47(6):1991-4. PMID: 12760882; PMCID: PMC155835.
    28. Nguyen T, Louie SG, Beringer P, Gill MA. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med. 2002 Nov; 8(6):521-8. PMID: 12394161.
      View in: PubMed
    29. Aminimanizani A, Beringer P, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother. 2002 Oct; 50(4):553-9. PMID: 12356801.
      View in: PubMed
    30. Beringer P, Aminimanizani A, Synold T, Scott C. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit. 2002 Apr; 24(2):315-21. PMID: 11897978.
      View in: PubMed
    31. Montgomery MJ, Beringer P, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001 Dec; 45(12):3468-73. PMID: 11709326; PMCID: PMC90855.
    32. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001 Nov; 7(6):434-40. PMID: 11706322.
      View in: PubMed
    33. Montgomery MJ, Beringer P, Louie SG, Gill MA. Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit. 2000 Dec; 22(6):695-700. PMID: 11128237.
      View in: PubMed
    34. Beringer P, Appleman MD. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med. 2000 Nov; 6(6):545-50. PMID: 11100967.
      View in: PubMed
    35. Beringer P, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000 Apr; 44(4):809-13. PMID: 10722474; PMCID: PMC89775.
    36. Beringer P. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med. 1999 Nov; 5(6):371-7. PMID: 10570739.
      View in: PubMed
    37. Beringer P, Wong-Beringer A, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. Ann Pharmacother. 1998 Feb; 32(2):176-81. PMID: 9496400.
      View in: PubMed
    38. Beringer P, Vinks AA, Jelliffe RW. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother. 1998 Jan; 41(1):142-4. PMID: 9511054.
      View in: PubMed
    39. Beringer P, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics. 1998 Jan; 13(1 Pt 1):35-49. PMID: 10175984.
      View in: PubMed